<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The availability of rh GM-CSF has allowed the in vivo treatment of patients with cytopenia </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore a phase I/II trial was initiated to study the effect of rh GM-CSF in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> who were not eligible for other kinds of therapy. rh GM-CSF has been tested in 10 patients in doses from 15 micrograms/m2 to 150 micrograms/m2 given intravenously over 8 hours for a cycle of 7 days followed by an interval of 14 days and a second 7-day treatment course </plain></SENT>
<SENT sid="2" pm="."><plain>A dose dependent increase in leukocyte count was observed in 9 out of 10 patients </plain></SENT>
<SENT sid="3" pm="."><plain>No change in reticulocyte numbers was seen and only one patient experienced an increase in platelet count </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity mainly consisted of mild local <z:mp ids='MP_0010140'>phlebitis</z:mp> at the site of infusion and sternal pain after bolus injection </plain></SENT>
<SENT sid="5" pm="."><plain>An increase in blast cell counts in some patients necessitated the start of low dose Ara-C therapy </plain></SENT>
</text></document>